Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.62 |
| ▸ | HSD17B3 | P37058 | 4/20 | 0.46 |
| ▸ | ANPEP | P15144 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17446878 | 0.88 | NOTUM (0.62) | NOTUMHSD17B3CNR2AMPD2 | |
| SCHEMBL6037236 | 0.84 | NOTUM (0.48) | NOTUMHSD17B3ANPEPTP53MAPT | |
| SCHEMBL6605105 | 0.83 | NOTUM (0.64) | NOTUMHSD17B3CNR2TP53MAPT | |
| SCHEMBL1607911 | 0.83 | NOTUM (0.64) | NOTUMHSD17B3CNR2MAPTKMT2A | |
| SCHEMBL6607583 | 0.81 | NOTUM (0.62) | NOTUMCNR2MAPTAMPD2ALDH1A1 | |
| SCHEMBL3025336 | 0.81 | NOTUM (0.62) | NOTUMHSD17B3ANPEPCNR2AMPD2 | |
| SCHEMBL5461555 | 0.81 | NOTUM (0.62) | NOTUMHSD17B3CNR2MAPTKMT2A | |
| SCHEMBL30630720 | 0.80 | KDM1A (0.41) | NOTUMCNR2KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15676877 | 0.80 | KDM1A (0.41) | NOTUMCNR2KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2204666 | 0.79 | NOTUM (0.59) | NOTUMHSD17B3MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| EP-2699562-B1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-20170334907-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-9676768-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2017-06-13 | — | — | US | disclosed |
| US-20150291586-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-9018214-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-28 | — | — | US | disclosed |
| US-20140179666-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| WO-2014089324-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2014-06-12 | — | — | WO | disclosed |
| EP-2699562-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | Astex Therapeutics Limited (GB) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143726-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-26 | — | — | WO | disclosed |
| WO-2005092853-A1 | METHOD FOR PRODUCING 5-BROMO-3,3-DIMETHYL-2,3-DIHYDRO-1H-INDOLE HYDROCHLORIDE | BAYER HEALTHCARE AG (DE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334907-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | NOTUM 3239/4885HSD17B3 1286/4885ANPEP 3279/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | NOTUM 3239/4885HSD17B3 1286/4885ANPEP 3279/4885 |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | NOTUM 3239/4885HSD17B3 1286/4885ANPEP 3279/4885 |
| US-20150291586-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | NOTUM 3239/4885HSD17B3 1286/4885ANPEP 3279/4885 |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | NOTUM 3239/4885HSD17B3 1286/4885ANPEP 3279/4885 |
| US-20140179666-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | NOTUM 3239/4885HSD17B3 1286/4885ANPEP 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.